Loading clinical trials...
Loading clinical trials...
Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients: Impact on Insulin Sensitivity, Glucose Tolerance, and Pharmacoeconomics
Conditions
Interventions
Pegvisomant
Somatostatin analog (lanreotide or octreotide)
Locations
1
Denmark
Department of Endocrinology, Aarhus University Hospital
Aarhus C, Aarhus, Denmark
Start Date
June 1, 2008
Primary Completion Date
November 1, 2009
Completion Date
May 1, 2011
Last Updated
January 26, 2012
NCT00001987
NCT07483723
NCT07460856
NCT00001595
NCT07297290
NCT06592261
Lead Sponsor
University of Aarhus
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions